2m 2m 2m 2m 2m 2m 2m
BLOSSOMHILL THER (BLSM)
NASDAQ
$14.62-$0.01 (-0.07%)
Price as of Oct 23, 2026 7:30 PM EDT- $465.0MMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
BLOSSOMHILL THER (BLSM)
$14.62-$0.01 (-0.07%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreDay Range
$14.50
$15.82
$14.63
1-Year Range
$13.94
$26.82
$14.63
Latest Close$14.63
Change
-$1.18 (-8.07%)
Volume80,688
Market Cap$465.0M
Shares Outstanding31.8M
P/E (TTM)-1.67
Diluted EPS (TTM)-$8.75
Enterprise Value$369.6M
Information as of 10/23/2026
Company Profile
BLOSSOMHILL THERAPEUTICS INC
https://bhtherapeutics.com$465.0M
Market Cap
-$23.8M
Net Income
Sector: Healthcare
Industry: Biotechnology
10255 Science Center Drive, San Diego, CA, United States, 92121
(858) 732-3880BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Key Executives
- Geoff Oxnard
- Jingrong Jean Cui
- Li Yishan
- Yishan Li
- Jason A. Keyes
Current Ownership Distribution
- Other29.1M (100.00%)
- Institutions0 (0.00%)
- Mutual Funds0 (0.00%)
- Insiders0 (0.00%)